DDInter1458 DDInter915
Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes.
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.
Phenylpropanolamine {u} (Compound) binds {v} (Gene) ADRB1
ADRB1 {u} (Gene) is bound by {v} (Compound) Indacaterol
Phenylpropanolamine {u} (Compound) causes {v} (Side Effect) Tachycardia
Tachycardia {u} (Side Effect) is caused by {v} (Compound) Indacaterol
Phenylpropanolamine {u} (Compound) binds {v} (Gene) ADRB2
ADRB2 {u} (Gene) is bound by {v} (Compound) Procaterol
Procaterol {u} (Compound) resembles {v} (Compound) Indacaterol
Phenylpropanolamine {u} (Compound) downregulates {v} (Gene) CSRP1
CSRP1 {u} (Gene) is downregulated by {v} (Compound) Procaterol
Procaterol {u} (Compound) resembles {v} (Compound) Indacaterol
Phenylpropanolamine {u} (Compound) binds {v} (Gene) ADRB2
ADRB2 {u} (Gene) is associated with {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Indacaterol
Phenylpropanolamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Salbutamol
Salbutamol {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Indacaterol
Phenylpropanolamine {u} (Compound) downregulates {v} (Gene) CSRP1
CSRP1 {u} (Gene) regulates {v} (Gene) ADRB2
ADRB2 {u} (Gene) is bound by {v} (Compound) Indacaterol
Phenylpropanolamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Salbutamol
Salbutamol {u} (Compound) binds {v} (Gene) ADRB1
ADRB1 {u} (Gene) is bound by {v} (Compound) Indacaterol
Phenylpropanolamine {u} (Compound) downregulates {v} (Gene) CSRP1
CSRP1 {u} (Gene) is regulated by {v} (Gene) UGT1A1
UGT1A1 {u} (Gene) is bound by {v} (Compound) Indacaterol
Phenylpropanolamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Formoterol
Formoterol {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Adrenergic beta2-Agonists {u} (Pharmacologic Class) includes {v} (Compound) Indacaterol
Phenylpropanolamine (Compound) binds ADRB1 (Gene) and ADRB1 (Gene) is bound by Indacaterol (Compound)
Phenylpropanolamine (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Indacaterol (Compound)
Phenylpropanolamine (Compound) binds ADRB2 (Gene) and ADRB2 (Gene) is bound by Procaterol (Compound) and Procaterol (Compound) resembles Indacaterol (Compound)
Phenylpropanolamine (Compound) downregulates CSRP1 (Gene) and CSRP1 (Gene) is downregulated by Procaterol (Compound) and Procaterol (Compound) resembles Indacaterol (Compound)
Phenylpropanolamine (Compound) binds ADRB2 (Gene) and ADRB2 (Gene) is associated with asthma (Disease) and asthma (Disease) is treated by Indacaterol (Compound)
Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol (Compound) treats asthma (Disease) and asthma (Disease) is treated by Indacaterol (Compound)
Phenylpropanolamine (Compound) downregulates CSRP1 (Gene) and CSRP1 (Gene) regulates ADRB2 (Gene) and ADRB2 (Gene) is bound by Indacaterol (Compound)
Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol (Compound) binds ADRB1 (Gene) and ADRB1 (Gene) is bound by Indacaterol (Compound)
Phenylpropanolamine (Compound) downregulates CSRP1 (Gene) and CSRP1 (Gene) is regulated by UGT1A1 (Gene) and UGT1A1 (Gene) is bound by Indacaterol (Compound)
Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class) and Adrenergic beta2-Agonists (Pharmacologic Class) includes Indacaterol (Compound)